Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986156 · 1 trial · 1 indication
Number of participants with all cause adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and number of participant deaths. AEs and laboratory values will be graded according to the NCI CTCAE version 4.03.
Number of Participants with laboratory abnormalities in specific thyroid tests. TSH = Thyroid stimulating hormone ULN = Upper limit number LLN = Lower limit number
Number of Participants with laboratory abnormalities in specific liver tests. ALT = alanine aminotransferase AST = aspartate aminotransferase ALP = alkaline phosphatase
| Arm | Type | Description |
|---|---|---|
| BMS-986156: Dose Escalation | EXPERIMENTAL | - |
| BMS-986156 + nivolumab (nivo): Dose Escalation | EXPERIMENTAL | - |
| BMS-986156: Dose Expansion | EXPERIMENTAL | - |
| BMS-986156 + nivolumab (nivo): Dose Expansion | EXPERIMENTAL | - |
| BMS986156 + Nivo: Cohort Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986156 | DRUG | - |
| Nivolumab | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * For Dose Escalation: * Subjects with any previously treated advanced (metastatic or refractory) solid tumor * For Cohort Expansion: * Subjects must have a previously tr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986156 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development and has been evaluated in patients with solid cancers or cancers that have spread. The drug is not yet approved and remains under clinical investigation.
BMS-986156 is a small molecule, but its specific molecular target has not been disclosed in the available information. It is being studied as an immuno-therapy, given alone or in combination with nivolumab, in patients with solid tumors.
BMS-986156 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
BMS-986156 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
BMS-986156 has been studied in one completed Phase 1 clinical trial, NCT02598960, which enrolled 295 patients with solid tumors. The trial evaluated the drug alone or in combination with nivolumab across multiple countries, including the United States, Australia, and several European nations.